Jin, J. X., Ginde, V., Huhn, S., Reichert, P., Bertsch, U., Fenk, R., Besemer, B., Boquoi, A., Schroers, R., Metzler, I. V., Hänel, M., Mann, C., Leypoldt, L., Heilmeier, B., Peters-Regehr, T., Scheid, C., Blau, I. W., Mueller-Tidow, C., Luntz, S., Holderried, T. A., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Shumilov, E., Knauf, W., Michel, C., Geer, T., Riesenberg, H., Lutz, C., Raab, M., Weinhold, N., Hoffmann, M., Benner, A., Findeisen, P., Weisel, K., Salwender, H., Mai, E. K., Goldschmidt, H. (2025). Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study. Blood. https://doi.org/10.1182/blood-2025-920